Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$57.5M
1 round on record
Latest round
$57.5M
Series D · Jun 2025 · 16 mo ago
Backers
2
Arboretum Ventures, Lightstone Ventures
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 5, 2025
Raised a round Series D $57.5M · led by Lightstone Ventures
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series D | Jun 2025 | $57.5M | Lightstone Ventures lead, ClavystBio lead | allaytx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Arboretum Ventures 
Lightstone Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
The Expertise To Deliver Results The Expertise To Deliver Results The Hicuity Health journey began in the intensive care unit, where we…
From strategic planning to implementation and ongoing support, we can guide you through every phase of your Salesforce journey.
Supporting patients every step of the way Evergreen Nephrology makes kidney care easier We work closely with patients and providers to help…
Revolutionizing acute pain management. Rebel is focused on developing disruptive, non-opioid solutions for acute pain.
Actionable Genomic Evidence at the Gene & Variant Level Aligned with ACMG/AMP. Supporting Patient Diagnosis & Precision Medicine for Rare…
Nivaan Care is India's most advanced non-surgical pain management clinic, treating back, neck, knee & shoulder pain with expert doctors &…
News
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Series D led by Lightstone Ventures and ClavystBio, supported by leading global syndicate of new and existing investors; Additional venture debt funding
Read more
Report
Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery
ATX101 is designed to provide extended pain relief after surgery, reducing the need for opioids and improving patient recovery Phase 2b registration trial is assessing the efficacy and safety of ATX101 for post-surgical pain management in total knee repla
Read more
Report
Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery
Read more
Report
Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery
Breakthrough Therapy designation supported by results from a Phase 2 dose-ranging trial Planned Phase 2B registrational trial expected to enroll 200 participants at U.S. sites SAN JOSE, CA, December 3, 2024 (BUSINESSWIRE) - Allay Therapeutics, a clinical-
Read more
Report
ATX101 Provided Sustained Pain Relief in TKA Patients: Results of an Exploratory Multicenter Double-Blind RCT
Read more
Report
Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company's Mission to Transform Post-Surgical Pain Management
Clinical Advisory Board will provide guidance as Allay advances ATX101 through registrational trials in total knee arthroplasty (TKA) and future indications Scientific Advisory Board will advise on CMC and non-clinical development as well as new pipeline
Read more
Report
Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery
Planned Phase 2b trial expected to enroll 200 participants at U.S. sites Study design and protocol informed by recent positive discussions with U.S. Food and Drug Administration Prior dose-ranging Phase 2b trial demonstrated durable treatment effects with
Read more
Report
Allay Therapeutics' Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Results inform design of pivotal Phase 2B study for potentially first ultra-sustained analgesic product Study concluded early for strong efficacy signals across multiple parameters Clinically meaningful reductions in patient pain relative to standard of c
Read more
Report
Show more news
Financials
Total raised
$57.5M
Latest round
Series D
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series D | 2025 | $57.5M | Details |